Vetra Bio

Name

Vetra Bio

Legal name

Vetra Bio Ltd

Website

https://vetrabio.com

Company type

Private

Founded year

2026

Operating status

Operating

Short description

Vetra Bio is a Cambridge, UK-based biotech that uses AI/ML at the intersection of computational modelling, molecular epigenetics, and translational science to decode ageing trajectories in companion animals, with a sales-led, subscription-based go-to-market targeting pet owners, veterinary networks, diagnostics companies, and translational biology organisations.

Ownership category

akta.pro rank

Product category

Animal Health Biotechnology

NAICS

Veterinary Services (54194)

akta.pro primary industry

Clinical Research, Trials & Translational Services (Veterinary Regenerative) (HLAMANAL)

akta.pro secondary industry

Practice Analytics & Business Intelligence (Dashboards, Benchmarking, Forecasting) (HLAMAGAI)

Keywords

• AI-driven animal longevity
• Computational biology
• Molecular epigenetics
• Companion animal health
• Translational science

Headquarters

HQ city

Trumpington

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Operations

Revenue model

1. Pre-revenue / Early Stage: Vetra Bio appears to be in an early pre-commercialization stage. The company is focused on research and development using AI/ML to understand companion animal ageing. Revenue generation mechanisms have not yet been disclosed publicly.

Go-to-market motion1 record

Marketing channels1 record

Core offering

Vetra Bio develops an AI/ML platform that decodes evolutionarily conserved ageing trajectories in companion animals, using computational modelling, molecular epigenetics, and translational science to understand how biological ageing can be shifted toward longer, healthier lives. The offering is a research-oriented platform aimed at enabling longevity and healthspan interventions for pets through data-driven biological analysis.

Differentiator

Problem solved

Functional benefit

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature1 record

Emerging players

• Cell Longevity / Span Biotech: Early-stage longevity biotech exploring companion animal healthspan applications of geroprotective interventions. Comparable as a peer in the niche of translational ageing science applied to pets.
• Embark Veterinary: Canine genetic testing and health-risk prediction company that uses genomic data and ML to predict disease and trait outcomes. Comparable as an AI/data-driven companion animal health platform with overlapping ML and predictive analytics capabilities.
• PetPace: Smart collar and health-monitoring platform collecting continuous biometric data on dogs and cats. Comparable as a data-driven companion animal health player, though focused on wearable sensing rather than AI/ML ageing trajectory modelling.
• Animal Biosciences: Veterinary biotech developing therapeutics to extend healthy lifespan in dogs. Comparable as an emerging player in the companion animal longevity space, with overlapping focus on healthspan extension in pets.

Direct peers

• Loyal for Dogs: Clinical-stage veterinary pharmaceutical company developing drugs to extend dog healthspan and lifespan. Directly comparable to Vetra Bio as both apply longevity science to companion animals, though Loyal focuses on pharmaceutical interventions rather than AI/ML trajectory analysis.
• Rejuvenate Bio: Biotech company developing gene therapies to reverse ageing in dogs, co-founded with Harvard's George Church. Comparable to Vetra Bio as a translational biotech targeting companion animal healthspan, though focused on gene therapy rather than AI-driven trajectory modelling.

Others

• Dog Aging Project (research consortium): Large NIH/University of Washington longitudinal study of ageing in companion dogs, generating one of the largest open companion animal health datasets. Comparable as an ecosystem participant generating translational ageing data that Vetra Bio could partner with or compete against.

Broad incumbents

• Antech Diagnostics (Mars Science & Diagnostics): Leading veterinary diagnostics platform offering reference lab and in-clinic testing. Comparable as a strategic buyer/channel partner for ageing-biomarker insights that Vetra Bio aims to produce for companion animal healthspan.
• Calico Life Sciences: Alphabet-backed longevity biotech pursuing ageing biology across species. Comparable as a broad incumbent in computational and molecular ageing science, though Vetra Bio is pet-specific and much earlier stage.
• Mars Petcare Biobank: Initiative by Mars Petcare generating large-scale genomic and health data on companion animals to advance pet longevity. Comparable as a well-capitalized player building longitudinal companion animal datasets for translational ageing research.

Market position

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vetra Bio